Lexaria Bioscience Corp - Warrants (11/01/2026)
LEXXW
Get informed when a big investor buys or sells
+ FollowMarket Cap$13M
Close$
$-1.66
138775% downside
Current Fair Value
138775% downsideOvervalued by 138775% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.00 Million |
|---|---|
| Enterprise Value | $9.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.66 |
| Beta | 0.34 |
| Outstanding Shares | 24,805,924 |
Return
| Return on Equity | -163.18% |
|---|---|
| Return on Assets | -161.71% |
| Return on Invested Capital | -175.94% |
Valuation & Multiples
| P/E Ratio | -1.79 |
|---|---|
| PEG | 3.78 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 49.57 |
| Enterprise Value to EBIT | -1.24 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
January 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lexaria Bioscience Corp
3 employeesLexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness...